Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Angiogene Pharmaceuticals Ltd.

Latest From Angiogene Pharmaceuticals Ltd.

MediciNova's Ibudilast Shows Potential In Progressive MS

The only approved treatment for primary progressive MS is Roche's Ocrevus but there is a possible competitor on the horizon following promising Phase II data which showed that ibudilast slowed brain shrinkage by nearly half.

Neurology Clinical Trials

Deals Shaping The Medical Industry, July-August 2012

The Dealmaking column is a survey of recent transactions, including strategic alliances, mergers & acquisitions, and financings, in the life sciences industries. Deals are listed by the following industry sectors: in vitro diagnostics, medical devices, pharmaceuticals, and research/analytical instrumentation and reagents. All transactions are excerpted from Elsevier's Strategic Transactions database, providing comprehensive transaction coverage from 1991 to the present.

BioPharmaceutical Medical Device

OXiGENE licenses Angiogene's know-how to support carcinoid syndrome PhII work

OXiGENE, a clinical-stage company based in South San Francisco, has gained worldwide rights to the intellectual property and know-how relating to Oxford, UK-based Angiogene Pharmaceuticals' vascular disrupting agent programme for neuroendocrine cancers, focused mainly on carcinoid syndrome.

See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals